SCHEMBL5264769

SCHEMBL5264769

CNc1ncnc(-c2cccnc2Oc2cc(C(=O)Nc3cc(OC[C@]4(C)CCCN4)cc(C(F)(F)F)c3)ccc2C)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 20/20 0.67
KDR P35968 17/20 0.67
LCK P06239 2/20 0.55
KIT P10721 2/20 0.55
SRC P12931 2/20 0.55
MAPK14 Q16539 2/20 0.55
JAK2 O60674 1/20 0.55
EGFR P00533 1/20 0.55
IGF1R P08069 1/20 0.55
MET P08581 1/20 0.55
FGFR1 P11362 1/20 0.55
FGFR2 P21802 1/20 0.55
FGFR4 P22455 1/20 0.55
FGFR3 P22607 1/20 0.55
ZAP70 P43403 1/20 0.55
MAPK10 P53779 1/20 0.55
BTK Q06187 1/20 0.55
YES1 P07947 1/20 0.55
AURKA O14965 1/20 0.45
ABL1 P00519 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5261499 0.92 TEK (0.67) TEKKDRLCKKITSRC
SCHEMBL5260759 0.88 TEK (0.60) TEKKDRLCKKITSRC
SCHEMBL5264044 0.85 TEK (0.58) TEKKDRLCKKITSRC
SCHEMBL1264244 0.85 TEK (0.80) TEKKDRLCKKITSRC
SCHEMBL5261770 0.85 TEK (0.59) TEKKDRLCKKITSRC
SCHEMBL1267447 0.82 TEK (0.67) TEKKDRLCKKITSRC
SCHEMBL5264772 0.82 TEK (0.67) TEKKDRLCKKITSRC
SCHEMBL1265362 0.82 TEK (0.75) TEKKDRLCKKITSRC
SCHEMBL5262308 0.81 TEK (0.54) TEKKDRLCKKITSRC
SCHEMBL1265143 0.81 TEK (1.00) TEKKDRLCKKITSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751136-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2007-02-14 EP claimed
WO-2005113494-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2005-12-01 WO claimed